Request Your Free Webinar Now:

"Combination Therapies Driving the Need for Expanded Genotypic Information: Case Studies of Microsatellite Instability Analysis and KRAS Variant Detection in Colorectal Cancer"

Interest in combinations of systemic and targeted therapies as well as the administration of multiple modalities -- such as small-molecule kinase inhibitors, monoclonal antibodies, and immunotherapy -- continues to increase.

The success of specific therapeutic combinations is attributed to a variety of factors: tumor-specific biology, such as gene mutations and the tumor microenvironment, as well as patient-specific attributes, such as their immune repertoire. Thus, gathering expanded tumor- and patient-specific genotypic information becomes critical to successfully identify which patients may benefit from specific combinations.

In this webinar, speakers discuss how genotypic biomarkers are being used to better understand cancer biology, develop prognostic markers, and predict therapeutic success.

Viewers will learn about:

• The changing landscape of combination cancer therapies and mutations of interest in colorectal cancer.
• The interplay of genotypic and phenotypic biomarkers in understanding underlying cancer pathophysiology.
• Implementing and optimizing fragment analysis-based MSI testing in formalin-fixed paraffin-embedded tissues.
• Targeted, highly accurate genotyping of key genetic biomarkers such as KRAS.

Offered Free by: Thermo Fisher Scientific
See All Resources from: Thermo Fisher Scientific